IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
• Year: 2000
Novartis Generics ac quired Labinca (Ar gen tina). Labinca spe cial izes in on col ogy, rheumatology, car dio -
vas cu lar and gas tro in tes ti nal diseases.
Novartis spun-off its Ag ri busi ness sec tor to its share hold ers as part of the trans ac tions nec es sary to form
Syngenta AG. On the same day AstraZeneca (UK) spun-off its Crop Pro tec tion ac tiv i ties which then
merged with Novartis’ Ag ri busi ness to form Syngenta AG.
CIBA Vi sion com pleted its ac qui si tion of Wes ley Jessen VisionCare.
Novartis Nu tri tion ac quired Heilpunkt Naturpharma (Ger many) from Lichtwer Pharma.
Ac quired Grandis Biotech (Ger many).
Hexal ac quired 100% of the US generics com pany Eon Labs Man u fac tur ing, based in New York.
• Year: 1999
Geneva Pharmaceuticals ac quired the as sets of Invamed Inc (USA) for SFr149 mil lion.
Novartis An i mal Health ac quired Vericore Hold ings Ltd (UK), a com pany fo cused on vac cines, para siti -
cides and other prod ucts for farm an i mals, pharmaceuticals for com pan ion an i mals, and aquaculture.
CIBA Vi sion an nounced that it had signed a deal to ac quire the intraocular lens busi ness of Men tor Corp
(USA).
Hexal ac quired Ilsan Iltas (Tur key) and es tab lished it as its sub sid iary in Tur key. Hexal also ac quired
Milen, one of the lead ing ac tive phar ma ceu ti cal in gre di ent man u fac tur ers in Turkey.
• Year: 1997
Novartis an nounced that a sec ond pro posal made to ac quire all out stand ing shares (28.8%) of SyStemix
(USA) had been de clined. SyStemix’s in de pend ent di rec tors de clined an orig i nal of fer in 1996.
• Year: 1996
The US FTC granted pro vi sional ap proval to the merger of Ciba and Sandoz to form Novartis. FTC ap -
proval was needed be cause Ciba and Sandoz had busi ness ar eas which over lapped in North Amer ica:
corn her bi cides, flea and tick con trol and gene ther apy. Sandoz’s corn her bi cide and an i mal health busi -
ness and the flea and tick busi ness had to be sold. In the area of gene ther apy, Novartis agreed to pro vide
ac cess to her pes sim plex vi rus thymidine kinase tech nol ogy, ex vivo gene ther apy, Fac tor VIII for he mo -
philia gene ther apy, and cytokines for use in cell ex pan sion for ex-vivo gene ther apy. Through the agree -
ment, the FTC aimed to es tab lish Rhone-Poulenc Rorer (now sanofi-aventis, France) as a vi a ble
com pet i tor to Novartis in the gene ther apy field. Novartis also agreed to pro vide cross-li censes of cer tain
Novartis gene therapy technologies to Chiron (USA).
Sandoz ac quired Ger man generics com pany, Azupharma, from Gehe (Ger many).
Sandoz ac quired Laboratoire Sodietal (France), an enteral clin i cal nu tri tion firm.
Sandoz Nu tri tion in creased its stake in Gazzoni (It aly) to 67%. It had held a ma jor ity stake in Gazzoni
since 1993.
© 2009 IMS Health In cor po rated or its af fil i ates Page 140